MNTA - One more comment on royalty split vs patent settlement terms:
The existing terms are clearly about preventing the entrance of another generic (i.e. secrecy) - something that patents are poorly designed to do per the licensing terms in the contract (e.g. the recent triggering of move to hybrid was a hair trigger - something the patents would have a hard time preventing). I would expect defense of the patents (including creating them) to be differently incentivized.
Momenta has noted for a long time that Sandoz, at the time of the Lovenox signing, did not believe in Momenta's IP edge - so it would be odd if they incentivized it the same way. (OTOH I'd expect the Copaxone patent split to be much closer to the same as the Profit Sharing split)
Market Data 
Markets 
AI
